Division of NeuroVirology, Beth Israel Deaconess Medical Center, E/CLS-1005, 330 Brookline Avenue, Boston, MA 02215, USA.
J Virol. 2011 Jul;85(14):7256-63. doi: 10.1128/JVI.02506-10. Epub 2011 May 4.
Progressive multifocal leukoencephalopathy (PML) is a severe demyelinating disease of the brain caused by JC virus (JCV). To assess the role of CD4(+) and CD8(+) T-cells against JCV in the clinical outcome of PML and PML in the setting of immune reconstitution inflammatory syndrome (IRIS), we tested gamma interferon (IFN-γ) response by enzyme-linked immunosorbent spot (ELISpot) and intracellular cytokine staining (ICS) in 117 subjects, including 66 PML patients with different clinical outcomes. Both assays were concordant and demonstrated that the cellular immune response against JCV is associated with better clinical outcome. PML survivors had an early CD8(+) T-cell response more frequently than PML progressors (100% versus 27.3%; P = 0.001), while only a trend was observed for the early CD4(+) T-cell response between these two groups (80% versus 45.5%; P = 0.18). Although IRIS itself was more frequent in the PML survivor group, there was no difference in IFN-γ-producing CD4(+) and CD8(+) T-cells between IRIS and non-IRIS PML patients, suggesting that T-cells expressing other cytokines likely have a role in the immunopathogenesis of IRIS. ELISpot and ICS assays are useful prognostic markers of PML evolution and may help in the clinical management of these patients.
进行性多灶性白质脑病(PML)是一种由 JC 病毒(JCV)引起的严重脑脱髓鞘疾病。为了评估 CD4(+)和 CD8(+)T 细胞对 PML 和免疫重建炎症综合征(IRIS)背景下 PML 中 JCV 的作用,我们通过酶联免疫斑点(ELISpot)和细胞内细胞因子染色(ICS)测试了 117 名受试者(包括 66 名具有不同临床结局的 PML 患者)的γ干扰素(IFN-γ)反应。两种检测方法均一致表明,针对 JCV 的细胞免疫反应与更好的临床结局相关。PML 幸存者比 PML 进展者更频繁地出现早期 CD8(+)T 细胞反应(100%比 27.3%;P = 0.001),而这两组之间早期 CD4(+)T 细胞反应仅呈趋势(80%比 45.5%;P = 0.18)。尽管 IRIS 本身在 PML 幸存者组中更为常见,但 IFN-γ 产生的 CD4(+)和 CD8(+)T 细胞在 IRIS 和非 IRIS PML 患者之间没有差异,这表明表达其他细胞因子的 T 细胞可能在 IRIS 的免疫发病机制中发挥作用。ELISpot 和 ICS 检测是 PML 进展的有用预后标志物,可能有助于这些患者的临床管理。